CMND — Clearmind Medicine Cashflow Statement
0.000.00%
Last trade - 00:00- $5.18m
- -$0.69m
Annual cashflow statement for Clearmind Medicine, fiscal year end - October 31st, USD millions except per share, conversion factor applied.
2020 October 31st | R2021 October 31st | R2022 October 31st | 2023 October 31st | 2024 October 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | Final | Final | Final |
| Net Income/Starting Line | -0.173 | -2.96 | -6.89 | -8.62 | -5.25 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | — | 0.681 | 1.85 | 3.23 | 0.475 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.023 | 0.021 | 1.24 | -0.969 | -0.13 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -0.197 | -2.25 | -3.72 | -6.3 | -4.86 |
| Capital Expenditures | -0.007 | -0.026 | -0.006 | 0 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.004 | -0.173 | 0 | -0.026 | -0.238 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.004 | -0.2 | -0.006 | -0.026 | -0.238 |
| Financing Cash Flow Items | -0.038 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.445 | 5.85 | 0.512 | 11.7 | 6.25 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.245 | 3.39 | -3.24 | 5.3 | 1.15 |